Caption Management’s Viking Therapeutics VKTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.92M Buy
305,000
+84,000
+38% +$2.7M 0.06% 340
2025
Q4
$7.77M Sell
221,000
-690,900
-76% -$24.5M 0.05% 393
2025
Q3
$24M Buy
911,900
+721,800
+380% +$21.5M 0.19% 117
2025
Q2
$5.04M Sell
190,100
-102,100
-35% -$2.69M 0.06% 407
2025
Q1
$7.06M Buy
292,200
+267,200
+1,069% +$8.44M 0.07% 280
2024
Q4
$1.01M Sell
25,000
-233,400
-90% -$13.3M 0.01% 912
2024
Q3
$16.4M Buy
258,400
+18,400
+8% +$1.08M 0.26% 89
2024
Q2
$12.7M Sell
240,000
-194,000
-45% -$12.7M 0.2% 115
2024
Q1
$35.6M Buy
434,000
+324,000
+295% +$14.4M 0.54% 34
2023
Q4
$2.05M Buy
110,000
+80,000
+267% +$1.05M 0.03% 613
2023
Q3
$332K Sell
30,000
-70,000
-70% -$1M 0.01% 1024
2023
Q2
$1.62M Hold
100,000
0.03% 558
2023
Q1
$1.67M Buy
+100,000
New +$1.03M 0.03% 497
2021
Q1
Sell
-50,000
Closed -$281K 1416
2020
Q4
$281K Hold
50,000
0.01% 807
2020
Q3
$290K Hold
50,000
0.01% 858
2020
Q2
$361K Hold
50,000
0.01% 728
2020
Q1
$234K Hold
50,000
0.01% 679
2019
Q4
$402K Sell
50,000
-175,000
-78% -$1.28M 0.01% 660
2019
Q3
$1.55M Buy
+225,000
New +$1.67M 0.08% 292

Other funds holding VKTX

Caption Management's VKTX Position: Q1 2026 in Review

Caption Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 36,880 shares — an estimated $1.19M sold.

Caption Management first reported a position in VKTX in Q1 2019 and held it in 11 quarters. The position peaked at $3.2M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Caption Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 36,880 Viking Therapeutics shares in Q1 2026, an estimated $1.19M.
  • Caption Management first reported a position in Viking Therapeutics in Q1 2019 and held it in 11 quarters.
  • Caption Management's Viking Therapeutics position peaked at $3.2M in Q1 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.